GlobeNewswire: Tempus Contains the last 10 of 39 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:53:21ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/06/01/2041609/0/en/Tempus-Launches-Prospective-Priority-Research-Study-and-Increases-Support-for-Oncology-Research-Initiatives-Despite-Pandemic-Challenges.html?f=22&fvtc=4&fvtv=32512Tempus Launches Prospective “Priority” Research Study and Increases Support for Oncology Research Initiatives Despite Pandemic Challenges2020-06-01T14:18:17Z<![CDATA[CHICAGO, June 01, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announces its study, along with a collaborative research initiative to expedite project needs during the COVID-19 pandemic. Many oncology research projects have been delayed as building the necessary datasets are difficult when patient volumes are down, both in clinic and for trials, and funding is sparse. However, Tempus is dedicating resources to keep those critical projects on track.]]>https://www.globenewswire.com/news-release/2020/05/31/2041232/0/en/Tempus-Launches-New-Precision-Medicine-Driven-Tests-Tempus-HRD-and-Tempus-TO.html?f=22&fvtc=4&fvtv=32512Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO2020-05-31T14:30:00Z<![CDATA[CHICAGO, May 31, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes. Tempus|HRD, a test that identifies a patient’s homologous recombination deficiency (HRD) status, and Tempus|TO, a test which predicts the tissue of origin (TO) for tumors, will both launch this summer in the U.S.]]>https://www.globenewswire.com/news-release/2020/05/30/2041225/0/en/Tempus-Launches-COVID-19-Specific-Clinical-and-Research-Initiatives-for-Oncology.html?f=22&fvtc=4&fvtv=32512Tempus Launches COVID-19-Specific Clinical and Research Initiatives for Oncology2020-05-30T14:30:00Z<![CDATA[CHICAGO, May 30, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a series of offerings designed to both advance vital research and support physicians in treating cancer patients, despite the challenges of the COVID-19 pandemic. Tempus is equipping physicians with the tools they need to treat high-risk patients while limiting their exposure to the virus, with mobile phlebotomy services, on-demand virtual case reviews, and COVID-19 PCR diagnostic testing for cancer patients.]]>https://www.globenewswire.com/news-release/2020/05/29/2041131/0/en/Tempus-TIME-Trial-Program-Reaches-Critical-Scale-and-Operational-Milestones.html?f=22&fvtc=4&fvtv=32512Tempus’ TIME Trial™ Program Reaches Critical Scale and Operational Milestones2020-05-29T19:55:41Z<![CDATA[CHICAGO, May 29, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials. To date, Tempus has signed up over 50 provider networks, over 30 unique biomarker trials, and has rapidly opened sites onto trials in an average of 10 days. Through the TIME Trial™ Program, Tempus is bringing the very best clinical trials to communities across the country, giving thousands of patients access to novel therapeutics.]]>https://www.globenewswire.com/news-release/2019/10/29/1937263/0/en/Tempus-Announces-the-Appointment-of-Scott-Gottlieb-MD-to-Its-Board-of-Directors.html?f=22&fvtc=4&fvtv=32512Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board of Directors2019-10-29T15:00:00Z<![CDATA[CHICAGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an advisor to Tempus and its leadership team, leveraging his vast experience as a medical policy expert and public health advocate to support Tempus as it harnesses the power and promise of big data and artificial intelligence to personalize patient care.]]>https://www.globenewswire.com/news-release/2019/09/30/1922669/0/en/Nature-Biotechnology-Study-Reveals-That-Tempus-xT-Platform-Increases-Cancer-Patients-Personalized-Therapeutic-Opportunities.html?f=22&fvtc=4&fvtv=32512Nature Biotechnology Study Reveals That Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities2019-09-30T15:00:00Z<![CDATA[CHICAGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today published a study in Nature Biotechnology, one of the industry’s leading peer-reviewed, scientific journals, surrounding its xT platform. The study, which focuses on 500 patient samples across diverse tumor types analyzed with the Tempus xT platform, found that those patients were matched to a broad range of therapies and trials based on deep molecular profiling and clinical data curation.]]>https://www.globenewswire.com/news-release/2019/09/03/1910293/0/en/Tempus-Expands-Its-Management-Team-With-the-Appointment-of-Lauren-Silvis-as-Senior-Vice-President-of-External-Affairs.html?f=22&fvtc=4&fvtv=32512Tempus Expands Its Management Team With the Appointment of Lauren Silvis as Senior Vice President of External Affairs2019-09-03T17:00:00Z<![CDATA[CHICAGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today the appointment of Lauren Silvis as its Senior Vice President of External Affairs. Silvis will oversee regulatory, public policy and government affairs, operating from Tempus’ office to be opened in Washington, D.C.]]>https://www.globenewswire.com/news-release/2019/08/22/1905623/0/en/Tempus-Expands-Leadership-Team-With-the-Appointment-of-Joel-Dudley-PhD-as-Senior-Vice-President-of-Research.html?f=22&fvtc=4&fvtv=32512Tempus Expands Leadership Team With the Appointment of Joel Dudley, PhD, as Senior Vice President of Research2019-08-22T16:00:00Z<![CDATA[CHICAGO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announces the appointment of Joel Dudley, PhD, as its Senior Vice President of Research. In his role, Dr. Dudley is responsible for leading Tempus’s research and development efforts for all non-oncology disease types, including cardiology and depression. His appointment signals Tempus’s further investment in advancing precision medicine solutions beyond cancer.]]>https://www.globenewswire.com/news-release/2019/06/11/1866811/0/en/Tempus-and-Leidos-Biomedical-Research-Inc-Launch-Effort-to-Enhance-The-Cancer-Genome-Atlas.html?f=22&fvtc=4&fvtv=32512Tempus and Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas2019-06-11T12:00:00Z<![CDATA[CHICAGO, June 11, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission to the National Cancer Institute’s Genomic Data Commons (GDC).]]>https://www.globenewswire.com/news-release/2019/06/03/1863365/0/en/Tempus-Announces-TIME-Trial-Service-a-New-Integrated-Molecular-Evaluation-that-Leverages-Artificial-Intelligence-to-Rapidly-Match-Cancer-Patients-to-Clinical-Trials.html?f=22&fvtc=4&fvtv=32512Tempus Announces (TIME) Trial Service, a New Integrated Molecular Evaluation that Leverages Artificial Intelligence to Rapidly Match Cancer Patients to Clinical Trials2019-06-03T14:30:00Z<![CDATA[CHICAGO, June 03, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today a new service, Tempus Integrated Molecular Evaluation (TIME) Trial, which aims to increase clinical trial enrollment and participation for cancer patients who are treated in both the academic and community setting. Approximately 1.7 million people will be diagnosed with cancer this year, yet less than five percent of patients participate in clinical trials. The TIME Trial is a proprietary platform that aims to solve this challenge by analyzing molecular and clinical patient data in real time and then routing patients to clinical trials at pre-qualified academic and community-based providers, ready to rapidly enroll patients or open the trial.]]>